Genmab completed the acquisition of Merus for $8bn.

Genmab, a biotechnology company, completed the acquisition of Merus, an oncology company, for $8bn. “The Merus acquisition marks a pivotal step in the delivery of Genmab’s long-term strategy and strengthens our path to becoming a global biotechnology leader with sustained growth and profitability. We are energized by the potential of petosemtamab to meaningfully impact the lives of people with head and neck cancer. Backed by our track record of successful development and commercial execution, we look forward to unlocking petosemtamab’s full potential and delivering on its promise to patients,” Jan van de Winkel, Genmab President and CEO.